Wedbush Equities Analysts Cut Earnings Estimates for KROS

Keros Therapeutics, Inc. (NASDAQ:KROS) – Stock analysts at Wedbush decreased their FY2024 earnings estimates for shares of Keros Therapeutics in a research report issued to clients and investors on Thursday, November 7th. Wedbush analyst Y. Zhong now forecasts that the company will post earnings of ($5.29) per share for the year, down from their prior estimate of ($5.14). Wedbush has a “Outperform” rating and a $84.00 price objective on the stock. The consensus estimate for Keros Therapeutics’ current full-year earnings is ($5.14) per share. Wedbush also issued estimates for Keros Therapeutics’ Q4 2024 earnings at ($1.40) EPS, Q1 2025 earnings at ($1.44) EPS, Q2 2025 earnings at ($1.46) EPS, Q3 2025 earnings at ($1.34) EPS, Q4 2025 earnings at ($1.36) EPS, FY2025 earnings at ($5.58) EPS, FY2026 earnings at ($5.54) EPS, FY2027 earnings at ($5.73) EPS and FY2028 earnings at ($4.73) EPS.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The firm had revenue of $0.39 million for the quarter. During the same period in the previous year, the business posted ($1.33) EPS. The business’s revenue was up 4750.0% compared to the same quarter last year.

Several other analysts have also issued reports on KROS. Scotiabank initiated coverage on shares of Keros Therapeutics in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $77.00 target price for the company. HC Wainwright reissued a “buy” rating and set a $100.00 price objective on shares of Keros Therapeutics in a research report on Thursday. Cantor Fitzgerald assumed coverage on Keros Therapeutics in a report on Thursday, October 24th. They issued an “overweight” rating on the stock. Guggenheim assumed coverage on Keros Therapeutics in a report on Monday, September 23rd. They set a “buy” rating and a $96.00 price target for the company. Finally, Bank of America decreased their price objective on Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating on the stock in a research note on Thursday, September 12th. Twelve equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Keros Therapeutics currently has an average rating of “Buy” and an average target price of $88.89.

Keros Therapeutics Stock Up 1.1 %

Keros Therapeutics stock opened at $67.91 on Monday. Keros Therapeutics has a 52-week low of $27.31 and a 52-week high of $73.00. The company has a market cap of $2.55 billion, a P/E ratio of -13.03 and a beta of 1.23. The business has a 50-day simple moving average of $58.19 and a two-hundred day simple moving average of $52.16.

Insider Buying and Selling at Keros Therapeutics

In related news, Director Carl L. Gordon sold 250,000 shares of the company’s stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $44.01, for a total transaction of $11,002,500.00. Following the completion of the transaction, the director now owns 119,522 shares in the company, valued at approximately $5,260,163.22. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 22.90% of the company’s stock.

Hedge Funds Weigh In On Keros Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in KROS. KBC Group NV raised its holdings in shares of Keros Therapeutics by 52.0% during the 3rd quarter. KBC Group NV now owns 1,263 shares of the company’s stock worth $73,000 after acquiring an additional 432 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in Keros Therapeutics by 26.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock worth $77,000 after purchasing an additional 280 shares during the last quarter. Values First Advisors Inc. purchased a new stake in Keros Therapeutics during the third quarter valued at $89,000. Ameritas Investment Partners Inc. lifted its position in Keros Therapeutics by 14.5% during the first quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company’s stock valued at $169,000 after purchasing an additional 324 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Keros Therapeutics in the 2nd quarter worth $128,000. 71.56% of the stock is owned by institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.